News | January 03, 2025
Veeda Group rebrands as Veeda Lifesciences
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Subscribe To Our Newsletter & Stay Updated
